Posted by Michael Wonder on 01 Jul 2025
Takeda announces US FDA approval of Gammagard Liquid ERC, the only ready to use liquid immunoglobulin therapy with low immunoglobulin A content
30 June 2025 - US commercialisation of Gammagard Liquid ERC projected to begin in 2026.
Takeda today announced that the US FDA has approved Gammagard Liquid ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready to use liquid immunoglobulin therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency.
